Specific miRNA expression profiles of non-tumor liver tissue predict a risk for recurrence of hepatocellular carcinoma

Hepatology Research

Volumn 44, Issue 6, 2014, Pages 631-638

  Utsunomiya, Tohru ^a   Ishikawa, Daichi ^a   Asanoma, Michihito ^a   Yamada, Shinichiro ^a   Iwahashi, Shuichi ^a   Kanamoto, Mami ^a   Arakawa, Yusuke ^a   Ikemoto, Tetsuya ^a   Morine, Yuji ^a   Imura, Satoru ^a   Ishibashi, Hiroki ^a   Takasu, Chie ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hepatocellular carcinoma; MiRNA microarray; Multicentric occurrence; Non tumor tissue; Recurrence

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 1258; MICRORNA 1321; MICRORNA 185; MICRORNA 18A; MICRORNA 18B; MICRORNA 1910; MICRORNA 211; MICRORNA 328; MICRORNA 515 3P; MICRORNA 517B; MICRORNA 518A 3P; MICRORNA 519D; MICRORNA 519E; MICRORNA 520D 3P; MICRORNA 520G; MICRORNA 521; MICRORNA 605; MICRORNA 613; MICRORNA BART2 5P; MICRORNA LET 7D; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER RESECTION; MALE; MICROARRAY ANALYSIS; MULTIPLE CANCER; ONCOGENE K RAS; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TUMOR RECURRENCE; UPREGULATION;

EID: 84901914956     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12164     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994; 35: 828-832.
4. Tarao K, Rino Y, Ohkawa S etal. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999; 86: 589-595.
5. Sakamoto M. Early HCC: diagnosis and molecular markers. J Gastroenterol 2009; 44: 108-111.
6. Utsunomiya T, Matsumata T, Adachi E etal. Limitations of current preoperative liver imaging techniques for intrahepatic metastatic nodules of hepatocellular carcinoma. Hepatology 1992; 16: 694-701.
7. Shimada M, Takenaka K, Gion T etal. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111: 720-726.
8. Utsunomiya T, Shimada M, Taguchi KI etal. Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma. J Am Coll Surg 2000; 190: 331-335.
9. Poon RT, Fan ST, Ng IO etal. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
10. Takenaka K, Adachi E, Nishizaki T etal. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology 1994; 19: 889-894.
11. Utsunomiya T, Okamoto M (equal contribution), Wakiyama S etal. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol 2006; 13: 947-954.
12. Utsunomiya T, Shimada M, Imura S etal. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol 2010; 45: 146-152.
13. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
14. van Rooij E, Sutherland LB, Liu N etal. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006; 103: 18255-18260.
15. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res 2006; 66: 10843-10848.
16. Schmittgen TD. Regulation of microRNA processing in development, differentiation and cancer. J Cell Mol Med 2008; 12: 1811-1819.
17. Lu J, Getz G, Miska EA etal. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
18. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174: 1131-1138.
19. Ji J, Shi J, Budhu A etal. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447.
20. Wong CM, Wong CC, Lee JM etal. Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012; 55: 1453-1461.
21. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012; 104: 528-540.
22. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edn. Tokyo: Kanahara Shuppan, 2009; 45.
23. Ueno S, Aoki D, Maeda T etal. Preoperative assessment of multicentric occurrence in synchronous small and multiple hepatocellular carcinoma based on image-patterns and histological grading of non-cancerous region. Hepatol Res 2004; 29: 24-30.
24. Hoshida Y, Villanueva A, Kobayashi M etal. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
25. Tsuchiya M, Parker JS, Kono H etal. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 2010; 9: 74.
26. Tanaka S, Mogushi K, Yasen M etal. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology 2011; 54: 1273-1281.
27. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207.
28. Portolani N, Coniglio A, Ghidoni S etal. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-235.
29. Sakon M, Umeshita K, Nagano H etal. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 2000; 135: 1456-1459.
30. Childs G, Fazzari M, Kung G etal. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 2009; 174: 736-745.
31. Davidson LA, Wang N, Shah MS etal. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 2009; 30: 2077-2084.
32. Jiao LR, Frampton AE, Jacob J etal. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One 2012; 7: e32068.
33. Tsang WP, Kwok TT. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009; 30: 953-959.
34. Li X, Pan YZ, Seigel GM etal. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 2011; 81: 783-792.
35. Xu XT, Xu Q, Tong JL etal. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer 2012; 106: 1320-1330.
36. Haraguchi N, Utsunomiya T, Inoue H etal. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506-513.
37. Tovuu LO, Imura S, Utsunomiya T etal. Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma. Int J Clin Oncol 2012; Jun 16. [Epub ahead of print].
38. Barry CT, D'Souza M, McCall M etal. Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant 2012; 12: 428-437.
39. Sato F, Hatano E, Kitamura K etal. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011; 6: e16435.